Search results

Page title matches

• N-methyl-d-aspartate receptor
  The '''N-methyl-d-aspartate receptor''' (NMDA receptor) is the binding site for [[glutamate]], [[n-methyl-d-aspa
  2 KB (323 words) - 10:56, 24 January 2010
• N-methyl-d-aspartate receptor/Approval
  12 bytes (1 word) - 01:53, 28 December 2007
• N-methyl-d-aspartate receptor/Definition
  123 bytes (13 words) - 23:43, 7 September 2009
• N-methyl-d-aspartate receptor/Related Articles
  Auto-populated based on [[Special:WhatLinksHere/N-methyl-d-aspartate receptor]]. Needs checking by a human.
  509 bytes (63 words) - 18:44, 11 January 2010

Page text matches

• NMDA receptor
  #REDIRECT [[N-methyl-d-aspartate receptor]]
  43 bytes (3 words) - 01:51, 28 December 2007
• NMDAR
  #REDIRECT [[N-methyl-d-aspartate receptor]]
  43 bytes (3 words) - 01:51, 28 December 2007
• N-methyl-d-aspartate receptor
  The '''N-methyl-d-aspartate receptor''' (NMDA receptor) is the binding site for [[glutamate]], [[n-methyl-d-aspa
  2 KB (323 words) - 10:56, 24 January 2010
• N-methyl-d-aspartate receptor/Related Articles
  Auto-populated based on [[Special:WhatLinksHere/N-methyl-d-aspartate receptor]]. Needs checking by a human.
  509 bytes (63 words) - 18:44, 11 January 2010
• Action potential/Related Articles
  {{r|N-methyl-d-aspartate receptor}}
  883 bytes (112 words) - 07:43, 8 January 2010
• Alzheimer's disease
  The [[N-methyl-d-aspartate receptor]] antagonist [[memantine]] has shown effectiveness<ref name="Areosa">
  16 KB (2,112 words) - 09:05, 25 October 2013
• Depersonalization disorder
  22 KB (3,027 words) - 01:56, 10 February 2010
• Opioid analgesic
  [[N-methyl-d-aspartate receptor]] (NMDA) activation may lead to neuropathic pain and tolerance.<ref name="p
  42 KB (5,792 words) - 07:29, 31 October 2014
• Schizophrenia
  ...ean B, Tamminga CA |title=Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia |jour
  27 KB (3,684 words) - 05:37, 3 April 2020
• Dementia
  ...ssociated with progression or prevention ([[cholinesterase inhibitor]]s, [[N-methyl-D-aspartate receptor]] antagonists, [[renin-angiotensin system]] blockers, and [[hydroxymethylgl
  54 KB (7,423 words) - 21:04, 1 May 2016